Belite 12-Month Interim Results of Phase 1b/2 Study in Adolescent Stargardt Disease Disappoint

 

• LBS-008 (aka Tinlarebant) was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time point
• The majority of the subjects showed stabilization of BCVA in at least one eye
• A trend for preventing or slowing expansion of autofluorescence continue to be observed
• No atrophic lesion (DDAF) in 12 of 13 subjects at the 12-month treatment period
• 12-month interim data from the ongoing Phase 2 study continue to show stabilization in several parameters, including halting or slowing lesion growth, preservation in retinal thickness, reduction in Ellipsoid Zone (EZ) defect width, and stabilization of visual acuity.

https://www.biospace.com/article/releases/belite-bio-presented-12-month-interim-results-of-lbs-008-phase-1b-2-study-in-adolescent-stargardt-disease-at-aao-annual-meeting-2022/